Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
784 000 KRW
0.38%
Market Closed
Updated:
May 16, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
14.9
Current
24.9
Median
3.9
Industry
Lower
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=14.9
Enterprise Value
/
55T
Revenue
3.7T
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.8T KRW | 14.9 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.1B USD | 5.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
195.6B USD | 4.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 6.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.7B USD | 3.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38B CHF | 5.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.6B USD | 9.1 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.2B USD | 3.5 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
25.9B USD | 8.6 | |
| US |
|
Waters Corp
NYSE:WAT
|
21.4B USD | 7.9 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 7.8 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
13.3
2-Years Forward
EV/S
11.4
3-Years Forward
EV/S
9.8
You don't have any saved screeners yet
